


AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1.-20. (Canceled)

21. (Currently Amended) A method for the ~~prevention or treatment of a dermatological condition at least one compound as defined by Claim 1, comprising administering to a patient in need of such prevention or treatment at least one compound having the formula (I):~~



wherein:

- R₁ represents

(i) the -CH₃ radical,

(ii) the radical -CH₂-O-R₆,


(iii) the radical -O-R₆, or

(iv) the radical -CO-R₇.

wherein the radicals R_6 and R_7 having the meanings given

below,

- Ar is one of the radicals of formulae (a) to (f):



wherein R_8 and R_9 having the meanings given below,

- R_2 and R_3 , which may be identical or different, represent a hydrogen atom or a lower alkyl radical,


- R_4 represents the radical $-(X)_m-(CH_2)_n-Y-(CH_2)_p-R_{10}$

the values m, n and p and the radicals X, Y and R_{10} having the meanings given below,

- R_5 represents a hydrogen or halogen atom, a lower alkyl radical or a radical $-O-R_6$,

- R_6 represents a hydrogen atom, a lower alkyl radical or a radical $-CO-R_{11}$,

- R₇ represents a hydrogen atom, a lower alkyl radical, a radical -OR₁₂ or a radical



wherein R' and R'', which may be identical or different, represent a hydrogen atom, a lower alkyl radical, a mono- or polyhydroxyalkyl radical, or an optionally substituted aryl radical, or alternatively, taken together, form a heterocycle,

wherein

- m is an integer equal to 0 or 1,

- n is an integer ranging from 1 to 6, inclusive,

- p is an integer ranging from 1 to 6, inclusive,

- X represents O or S(O)_q,

- Y represents O or S(O)_q,

- q is an integer ranging from 0 to 2, inclusive,

- R₈ represents a hydrogen or halogen atom, a lower alkyl radical or a radical -O-R₆,

- R₉ represents a hydrogen atom, a lower alkyl radical or a radical -CO-R₁₁,

- R₁₀ represents a mono- or polyhydroxyalkyl radical wherein the hydroxyls are optionally protected in the form of methoxy, ethoxy, acetoxy or acetonide, a radical -CO-R₇ or an optionally substituted aryl or aralkyl radical,

- R₁₁ represents a lower alkyl radical,



- R₁₂ represents a hydrogen atom, an alkyl radical, an alkenyl radical,

a mono- or polyhydroxyalkyl radical in which the hydroxyls are optionally protected in the form of methoxy, ethoxy, acetoxy or acetonide, or an optionally substituted aryl or aralkyl radical, or a salt thereof, or an optical or geometrical isomer thereof.

22. (Currently Amended) The method as defined by Claim 21, wherein said dermatological condition comprises ~~a condition involving~~ at least one of common acne, comedones, polymorphonuclear leukocytes, acne rosacea, nodulocystic acne, acne conglobata, senile acne, ~~secondary acnes,~~ solar acne, medication-induced acne, occupational acne, ichthyosis, an ichthyosiform ~~states~~ state, Darrier's disease, palmoplantar keratoderma, leucoplasia, a leucoplasiform state, cutaneous or mucous (buccal) lichen, ~~keratinization disorder having an inflammatory and/or immuneallergic component,~~ cutaneous, mucous or ungual psoriasis, psoriatic rheumatism, ~~cutaneous atopy,~~ eczema, respiratory atopy, gingival hypertrophy; ~~inflammatory complaints which do not exhibit a disorder of keratinization; dermal or epidermal proliferations, common warts, flat warts and~~ wart, flat wart, verruciform epidermodysplasia, oral or florid ~~papillomatoses~~ papillomatosis, basocellular and or spinocellular ~~epitheliomas;~~ epithelioma, bullosis, and a collagen ~~disease, diseases;~~ ophthalmological disorders, corneopathies; corneopathy, light-induced and chronological aging of the skin, actinic ~~keratoses and pigmentations;~~ keratosis or pigmentation, stigmata of epidermal and/or dermal atrophy induced by local or systemic corticosteroids[[,]] or other skin atrophy; a ~~cicatrization disorders~~ disorder, stretch marks; ~~sebaceous functioning,~~

hyperseborrhoea of acne or simple seborrhoea; a cancerous or precancerous states state, promyelocytic leukemias; ~~inflammatory complaints~~, arthritis; ~~viruses~~; Karposi's syndrome, alopecia; ~~dermatological complaints having an immunological component~~; ~~complaints of the cardiovascular system~~, arteriosclerosis, hypertension, insulin-independent diabetes; or a skin disorders disorder due to exposure to UV radiation.

23. (Currently Amended) A method for the ~~prevention or~~ treatment of a dermatological condition ~~involving~~ comprising an inflammatory and/or immunoallergic keratinization disorder ~~having an inflammatory and/or immunoallergic component~~, said method comprising administering an effective amount of at least one stilbene compound to a patient in need of such treatment, ~~and~~ said at least one stilbene compound having the formula (I):




wherein:

- R_1 represents

- (i) the $-CH_3$ radical,
- (ii) the radical $-CH_2-O-R_6$,
- (iii) the radical $-O-R_6$, or
- (iv) the radical $-CO-R_7$,

wherein the radicals R_6 and R_7 having the meanings given below,

- Ar represents a radical selected from the group consisting of one of the radicals of formulae (a) to (f):




wherein R_8 and R_9 having the meanings given below,

- R_2 and R_3 , which may be identical or different, represent a hydrogen atom or a lower alkyl radical,

- R_4 represents the radical $-(X)_m-(CH_2)_n-Y-(CH_2)_p-R_{10}$

the values m , n and p and the radicals X , Y and R_{10} having the meanings given below,

- R₅ represents a hydrogen or halogen atom, a lower alkyl radical or a radical
- O-R₆,
- R₆ represents a hydrogen atom, a lower alkyl radical or a radical -CO-R₁₁,
- R₇ represents a hydrogen atom, a lower alkyl radical, a radical -OR₁₂ or a radical



wherein R' and R'', which may be identical or different, represent a hydrogen atom, a lower alkyl radical, a mono- or polyhydroxyalkyl radical, ~~an amine acid or peptide or sugar residue~~, or a phenyl radical optionally substituted with a substituent selected from the group consisting of a halogen atom, a hydroxyl radical, an alkyl radical, a nitro function, a methoxy group and an optionally substituted amine function, or alternatively, taken together, R' and R'' form a heterocycle,

wherein

- m is an integer equal to 0 or 1,
- n is an integer ranging from 1 to 6, inclusive,
- p is an integer ranging from 1 to 6, inclusive,
- X represents O or S(O)_q,
- Y represents ~~O, S(O)_q or N-R₉~~, O or S(O)_q,
- q is an integer ranging from 0 to 2, inclusive,
- R₈ represents a hydrogen or halogen atom, a lower alkyl radical or a radical
- O-R₆,

- R₉ represents a hydrogen atom, a lower alkyl radical or a radical -CO-R₁₁,
 - R₁₀ represents a mono- or polyhydroxyalkyl radical wherein the hydroxyls are optionally protected in the form of methoxy, ethoxy, acetoxy or acetonide, a radical -CO-R₇ or a benzyl or phenethyl radical, optionally substituted with a substituent selected from the group consisting of a halogen atom, a hydroxyl, a nitro function and a methoxy group,
 - R₁₁ represents a lower alkyl radical,
 - R₁₂ represents a hydrogen atom, an alkyl radical, an alkenyl radical, a mono- or polyhydroxyalkyl radical in which the hydroxyls are optionally protected in the form of methoxy, ethoxy, acetoxy or acetonide, ~~a sugar residue or an amino acid or peptide residue,~~ a phenyl radical optionally substituted with a substituent selected from the group consisting of a halogen atom, a hydroxyl radical, an alkyl radical, a nitro function, a methoxy group and an optionally substituted amine function, or a benzyl or phenethyl radical, optionally substituted with a substituent selected from the group consisting of a halogen atom, a hydroxyl, a nitro function and a methoxy group,
- or ~~salts thereof or~~ a salt thereof, or an optical or geometrical isomers isomer thereof.

24. (Currently Amended) ~~The method as defined by Claim 23, said A~~
method for the treatment of a dermatological condition comprising an inflammatory
and/or immunoallergic keratinization disorder, said method comprising administering
an effective amount of at least one stilbene compound to a patient in need of such

treatment, said at least one stilbene compound being selected from the group consisting of:

Ethyl 4-[(E)-2-(3-(1-adamantyl)-4-methoxyethoxy-methoxyphenyl)ethenyl]benzoate;

4-[(E)-2-(3-(1-Adamantyl)-4-methoxyethoxymethoxy-phenyl)ethenyl]benzoic acid;

Ethyl 4-[(E)-2-(3-(1-adamantyl)-4-methoxyethoxy-methoxyphenyl)-1-propenyl]benzoate;

4-[(E)-2-(3-(1-Adamantyl)-4-methoxyethoxymethoxy-phenyl)-1-propenyl]benzoic acid;

4-[(Z)-2-(3-(1-Adamantyl)-4-methoxyethoxymethoxy-phenyl)-1-propenyl]benzoic acid;

Methyl 5-{2-[3-adamant-1-yl-4-(2-methoxyethoxy-methoxy)phenyl]propen-(E)-yl}pyridine-2-carboxylate;

5-{2-[3-Adamant-1-yl-4-(2-methoxyethoxymethoxy)-phenyl]propen-(E)-yl}pyridine-2-carboxylic acid;

5-{2-[3-Adamant-1-yl-4-(2-methoxyethoxymethoxy)-phenyl]propen-(Z)-yl}pyridine-2-carboxylic acid;

Ethyl 6-{2-[3-adamant-1-yl-4-(2-methoxyethoxymethoxy)phenyl]propen-(E)-yl}nicotinate;

6-{2-[3-Adamant-1-yl-4-(2-methoxyethoxymethoxy)-phenyl]propen-(E)-yl}nicotinic acid;

6-{2-[3-Adamant-1-yl-4-(2-methoxyethoxymethoxy)-phenyl]propen-(Z)-yl}nicotinic acid;

Methyl 4-{2-[3-adamant-1-yl-4-(2-methoxyethoxy-methoxy)phenyl]propen-(Z)-yl}-2-methoxybenzoate;

4-{2-[3-Adamant-1-yl-4-(2-methoxyethoxymethoxy)-phenyl]propen-(E)-yl}-2-methoxybenzoic acid;

4-{2-[3-Adamant-1-yl-4-(2-methoxyethoxymethoxy)-phenyl]propen-(Z)-yl}-2-methoxybenzoic acid;

Ethyl 4-{2-[3-adamant-1-yl-4-(3-ethoxymethoxypropyl)phenyl]propen-(E/Z)-yl}benzoate;

4-{2-[3-Adamant-1-yl-4-(3-ethoxymethoxypropyl)phenyl]propen-(E)-yl}benzoic acid;

4-{2-[3-Adamant-1-yl-4-(3-ethoxymethoxypropyl)phenyl]propen-(Z)-yl}benzoic acid;

Ethyl 4-{2-[3-adamant-1-yl-4-(3-benzyloxypropyl)-phenyl]propen-(E/Z)-yl}-benzoate;

4-{2-[3-Adamant-1-yl-4-(3-benzyloxypropyl)phenyl]-propen-(E)-yl}-benzoic acid;

4-{2-[3-Adamant-1-yl-4-(3-benzyloxypropyl)phenyl]-propen-(Z)-yl}benzoic acid;

Ethyl 4-{2-[3-adamant-1-yl-4-(3-diethylcarbamoylmethoxypropyl)phenyl]propenyl}benzoate;

4-{2-[3-Adamant-1-yl-4-(3-diethylcarbamoylmethoxypropyl)phenyl]propenyl}benzoic acid;

Ethyl 4-{2-[3-adamant-1-yl-4-(3-carboxymethoxypropyl)phenyl]propenyl}benzoate;

4-{2-[3-Adamant-1-yl-4-(3-carboxymethoxypropyl)-phenyl]propenyl}benzoic acid;

Ethyl 4-{2-[3-adamant-1-yl-4-(3-carbamoylmethoxypropyl)phenyl]propenyl}benzoate;

4-{2-[3-Adamant-1-yl-4-(3-carbamoylmethoxypropyl)-phenyl]propenyl}benzoic acid;

N-Ethyl-4-[(E)-2-(3-(1-adamantyl)-4-methoxyethoxy-methoxyphenyl)-1-propenyl]benzamide;

4-[(E)-2-(3-(1-Adamantyl)-4-methoxyethoxymethoxy-phenyl)-1-propenyl]benzamide;

N-4-(Hydroxyphenyl)-4-[(E)-2-(3-(1-adamantyl)-4-methoxyethoxymethoxyphenyl)-1-propenyl]benzamide;

4-[(E)-2-(3-(1-Adamantyl)-4-methoxyethoxymethoxy-phenyl)-1-propenyl]benzenemethanol;

4-[(E)-2-(3-(1-Adamantyl)-4-methoxyethoxymethoxy-phenyl)-1-propenyl]benzaldehyde;

4-[(E)-2-(3-(1-Adamantyl)-4-methoxyethoxymethoxy-phenyl)-1-propenyl]phenol;

4-[(E)-2-(3-(1-Adamantyl)-4-methoxyethoxymethoxy-phenyl)-1-propenyl]benzoic acid morpholide; ~~or~~ and

4-[(E)-2-(3-(1-Adamantyl)-4-methoxyethoxymethyl-sulphanylphenyl)-1-propenyl]benzoic acid; ~~and~~

~~mixtures thereof.~~

25. (New) The method according to Claim 23, wherein the dermatological condition comprises psoriasis, cutaneous atopy, respiratory atopy or gingival hypertrophy.

26. (New) The method according to Claim 23, wherein the dermatological condition comprises cutaneous psoriasis, mucous psoriasis, ungual psoriasis, psoriatic rheumatism, eczema, respiratory atopy or gingival hypertrophy.

27. (New) The method according to Claim 24, wherein the dermatological condition comprises psoriasis, cutaneous atopy, respiratory atopy or gingival hypertrophy.

28. (New) The method according to Claim 24, wherein the dermatological condition comprises cutaneous psoriasis, mucous psoriasis, ungual psoriasis, psoriatic rheumatism, eczema, respiratory atopy or gingival hypertrophy.